BioLife Solutions, Inc.

How big is BioLife Solutions, Inc.?

As of Jun 18, BioLife Solutions, Inc. has a market capitalization of $1,033.98 million, with net sales of $105.55 million and a net profit of -$11.30 million over the latest four quarters. The balance sheet shows shareholder's funds of $348.91 million and total assets of $404.34 million.

As of Jun 18, BioLife Solutions, Inc. has a market capitalization of 1,033.98 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 105.55 million for the latest four quarters, while the net profit for the same period was -11.30 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 348.91 million and total assets of 404.34 million.

What does BioLife Solutions, Inc. do?

BioLife Solutions, Inc. develops and markets biopreservation tools for cells, tissues, and organs in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $24 million and has a market cap of approximately $1.03 billion.

Overview: <BR>BioLife Solutions, Inc. is engaged in the development, manufacturing, and marketing of biopreservation tools and services for cells, tissues, and organs, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 24 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,033.98 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.21 <BR>Return on Equity: -2.05% <BR>Price to Book: 2.93<BR><BR>Contact Details: <BR>Address: 3303 Monte Villa Pkwy Ste 310, BOTHELL WA: 98021-6200 <BR>Tel: ['1 425 4011400', '1 425 4021400'] <BR>Fax: 1 425 4021433 <BR>Website: https://biolifesolutions.com/

Should I buy, sell or hold BioLife Solutions, Inc.?

Who are in the management team of BioLife Solutions, Inc.?

As of March 2022, the management team of BioLife Solutions, Inc. includes Mr. Raymond Cohen (Independent Chairman), Mr. Michael Rice (President and CEO), Mr. Andrew Hinson (Independent Director), and Mr. Joseph Schick (Independent Director). They oversee the company's strategic direction and operations.

As of March 2022, the management team of BioLife Solutions, Inc. includes the following individuals:<BR><BR>- Mr. Raymond Cohen, who serves as the Independent Chairman of the Board.<BR>- Mr. Michael Rice, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Andrew Hinson, who is an Independent Director.<BR>- Mr. Joseph Schick, who is also an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Is BioLife Solutions, Inc. overvalued or undervalued?

As of February 28, 2022, BioLife Solutions, Inc. is considered overvalued and has a risky valuation grade due to poor financial metrics, including a high Price to Book Value of 3.20, negative EV to EBIT and EV to EBITDA ratios, and underperformance compared to the S&P 500, particularly with a 3-year return of 13.67% versus 70.41% for the index.

As of 28 February 2022, the valuation grade for BioLife Solutions, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 3.20 and an EV to Capital Employed ratio of 3.78, which suggest that the market is pricing the company at a premium despite its losses. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -137.15 and -1053.88 respectively highlight significant operational challenges.<BR><BR>In comparison to peers, BioLife Solutions has a P/E ratio of -62.83, while Artivion, Inc. shows a much larger negative P/E of -268.22, and Embecta Corp. stands out with a positive P/E of 6.42, indicating that BioLife is struggling more than its peers. The company's stock has underperformed against the S&P 500 over multiple periods, notably with a 3-year return of 13.67% compared to the S&P 500's 70.41%, reinforcing the notion that it is overvalued in the current market context.

Is BioLife Solutions, Inc. technically bullish or bearish?

As of October 3, 2025, BioLife Solutions, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite mixed signals from the KST and underperformance compared to the S&P 500 over various time frames.

As of 3 October 2025, the technical trend for BioLife Solutions, Inc. has changed from sideways to bullish. The weekly and monthly MACD indicators are bullish, supporting this positive stance. The Bollinger Bands also indicate a bullish trend on both weekly and monthly time frames. Daily moving averages are bullish, further reinforcing the bullish sentiment. However, the KST shows a mixed signal with a bullish weekly reading and a mildly bearish monthly reading. The Dow Theory indicates no trend on both weekly and monthly time frames.<BR><BR>In terms of performance, BioLife Solutions has underperformed the S&P 500 over the 1-month, 1-year, 3-year, and 5-year periods, with returns of 0.23%, 8.07%, 12.18%, and -10.10%, respectively, compared to 4.15%, 17.82%, 82.57%, and 100.56% for the S&P 500. Overall, the current technical stance is bullish, albeit with some caution due to mixed signals in certain indicators.